Genmab Announces Financial Results for the First Nine Months of 2019
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: GlobeNewswire
November 6, 2019; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2019 Highlights Completion of public offering and listing of American Depository Shares (ADSs) on Nasdaq Global Select Market under the symbol “GMAB.” Total gross proceeds from the issuance of new shares amounted to USD 582 million (DKK 3,873 million) with a corresponding increase in share capital of 3,277,500 ordinary shares or 32,775,000 ADSsPositive data reported by Novartis for the Phase III ASCLEPIOS I & II studies of subcutaneous ofatumumab in relapsing multiple sclerosis (RMS)DARZALEX® (daratumumab) approved in the U.S. in combination with bortezomib, thalidomide and dexamethasone (VTd) and in Japan in combination with bortezomib, melphalan and prednisone (VMP) in various multiple myeloma frontline settings Positive topline results for daratumumab in both the Phase III CANDOR and Phase II GRIFFIN studies in various multiple myeloma settingsBiologics License Application (BLA)
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Genmab A/S (NASDAQ: GMAB) was upgraded by analysts at Sanford C. Bernstein from a "strong sell" rating to a "hold" rating.MarketBeat
- Antibody Discovery Market Industry Forecast Report 2024-2035, Featuring Ablexis, ChemPartner, Creative Biolabs, GenScript, Genmab, Harbour BioMed, MabSilico, Nona Biosciences, WuXi Biologics and More [Yahoo! Finance]Yahoo! Finance
- FairJourney Biologics Establishes Scientific Advisory Board [Yahoo! Finance]Yahoo! Finance
- Genmab A/S: Circling Back On This Complicated Story [Seeking Alpha]Seeking Alpha
- Genmab to Hold 2024 R&D Update and ASH Data Review Meeting [Yahoo! Finance]Yahoo! Finance